There are all kinds of treatments that turned out effective against the novel coronavirus-produced disease, covid 19. Now, AstraZeneca is making headlines due to its own treatment.
AstraZeneca’s treatment is efficient
CNBC revealed that AstraZeneca’s antibody treatment has been shown to be highly effective at preventing Covid-19 in people who may not respond well to vaccines. This is according to new clinical trial results.
The official notes revealed that the data showed that patients given a single injection of the antibody treatment, known as AZD7442, were 83% less likely to develop symptomatic cases of the covid 19 than participants who were given a placebo.
The same article that addressed the news revealed that an earlier analysis of the trial, conducted three months after the treatment was administered, had shown that the risk of developing severe disease was reduced by 77%.
“Six months on from the treatment being administered, no severe cases of Covid-19 or deaths from the virus had been recorded among patients given the antibody cocktail,” the conclusion reads.
It’s been also reported that in a separate trial, patients with mild to moderate symptoms of the disease who got the treatment within three days of developing symptoms had their risk of developing severe symptoms reduced by 88%.
“These compelling results give me confidence that this long-acting antibody combination can provide my vulnerable patients with the long-lasting protection they urgently need to finally return to their everyday lives.”
This is what Hugh Montgomery, professor of intensive care medicine at University College London and principal investigator in the trials, said in a press release Thursday.
Covid treatment breakthrough
Earlier today, we revealed more good news about covid treatments.
Nih.gov just noted that the lung autopsy and plasma samples from people who died of the terrible disease had provided a clearer picture of how the virus spreads and damages lung tissue.
It’s been reported that the scientists at the National Institutes of Health and their collaborators say the information, published in Science Translational Medicine, could help predict severe and prolonged covid 19 cases, especially among high-risk people, and inform effective treatments.
